What is the history of Multiple myeloma?

Multiple myeloma is a cancer of plasma cells that was first clinically described in 1844 by Dr. Samuel Solly and later characterized by Henry Bence Jones, who identified the diagnostic "Bence Jones protein" in urine. Since its initial identification as a mysterious "mollities ossium" (softening of the bones), medical understanding of multiple myeloma has transformed from a fatal, untreatable diagnosis into a manageable condition with significantly improved survival rates through targeted therapies.

How was multiple myeloma first discovered?

The history of multiple myeloma began in 1844 when a London merchant named Thomas Alexander McBean presented with severe bone pain and fragility. Dr. Samuel Solly documented his case, but it was the chemist Henry Bence Jones who famously analyzed the patient's urine, discovering a unique protein that precipitated when heated. This protein, now known as the Bence Jones protein, remains a cornerstone in the diagnosis of multiple myeloma today.

How has our understanding of multiple myeloma evolved?

For over a century, multiple myeloma was considered a rare, uniform disease of the bone marrow. It was not until the mid-20th century that researchers began to distinguish it from other hematological malignancies. With the advent of modern cytogenetics and molecular biology, we now recognize multiple myeloma as a heterogeneous collection of plasma cell dyscrasias, often driven by specific chromosomal translocations and genetic mutations.

What are the major milestones in the treatment of multiple myeloma?

The treatment landscape for multiple myeloma has shifted drastically from palliative care to life-extending precision medicine:

• 1950s: The introduction of melphalan, the first chemotherapy agent for the disease.


• 1980s: The emergence of high-dose chemotherapy combined with autologous stem cell transplantation.


• 2000s–Present: The "immunotherapy revolution," including proteasome inhibitors (e.g., bortezomib), immunomodulatory drugs (e.g., lenalidomide), and monoclonal antibodies (e.g., daratumumab).

How has patient advocacy changed the landscape?

Historically, multiple myeloma patients faced extreme isolation due to the rarity and severity of the condition. Today, advocacy groups and platforms like DiseaseMaps.org—which connects 217 community members living with multiple myeloma—have empowered patients to become active partners in their care, driving funding for clinical trials and accelerating access to life-saving therapies.

Next steps

• Consult a hematologist-oncologist specializing in plasma cell disorders.


• Connect with the 217 members on DiseaseMaps.org to share experiences and coping strategies.


• Discuss current clinical trial opportunities with your medical team to explore emerging therapies.

Medical disclaimer: This content is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Multiple Myeloma


• International Myeloma Foundation (IMF)


• OMIM (Online Mendelian Inheritance in Man)